Bayer HealthCare announced the approval of Safyral (drospirenone/ethinyl estradiol/levomefolate calcium tablets and levomefolate calcium tablets), an oral contraceptive that raises folate levels in ...
WAYNE, N.J. — The Food and Drug Administration has approved a new oral contraceptive developed by Bayer. Safyral is a combination of Yasmin, also developed by Bayer, with 451 mcg levomefolate calcium, ...
WAYNE, N.J., Dec. 16, 2010 Bayer HealthCare Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new oral contraceptive (OC), SAFYRAL(TM) (drospirenone 3 mg ...
The US Court of Appeals for the Federal Circuit on Friday ruled that a Merck KGaA patent - linked to two of Bayer’s oral contraceptives, Safyral and Beyaz - is invalid because ingredients in the drug ...
Bayer HealthCare Pharmaceuticals, Inc. announced the US Food and Drug Administration (FDA) has approved a new oral contraceptive (OC), Safyral (drospirenone 3 mg/ ethinyl estradiol 30 mcg/ ...
Actavis, Inc. recently confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) seeking approval to market drospirenone/ethinyl ...
Safyral is engineered to reduce the risks of rare neural tube defects. Combination oral contraceptives reduce the risk of pregnancy primarily by inhibiting ovulation. This product combines ...
Lupin has received final approval for its Tydemy from the United States Food and Drug Administration to market a generic version of Safyral Tablets of Bayer Healthcare Pharmaceuticals Inc.Source : BSE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results